학술논문
Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention
Document Type
Academic Journal
Source
Journal of the American College of Cardiology. March 7, 2006, Vol. 47 Issue 5, p939, 5 p.
Subject
Language
English
ISSN
0735-1097
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jacc.2005.10.047 Byline: Steven R. Steinhubl ([cor]), Peter B. Berger, Danielle M. Brennan, Eric J. Topol Abbreviations: GP, glycoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; UTVR, urgent target vessel revascularization Abstract: Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention Steven R. Steinhubl, Peter B. Berger, Danielle M. Brennan, Eric J. Topol, for the CREDO Investigators To determine the optimal timing of a 300-mg clopidogrel loading dose before a percutaneous coronary intervention (PCI), pre-treatment timing data from 1,762 patients in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial were analyzed using linear splines to summarize the effect of time of pre-treatment as a continuous variable. The difference in the 28-day combined end point of death, myocardial infarction, and urgent target vessel revascularization was not significant between placebo- and clopidogrel-pre-treated patients until [greater than or equal to]15 h pre-treatment, with a 58.8% (p = 0.028) relative reduction in the primary end point in patients pre-treated with clopidogrel [greater than or equal to]15 h compared with placebo. Author Affiliation: ([cor]) Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, Kentucky (a ) Duke Clinical Research Institute, Duke University, Durham, North Carolina (a ) Cleveland Clinic Foundation, Duke University, Durham, North Carolina (As.) Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio Article History: Received 28 March 2005; Revised 4 October 2005; Accepted 10 October 2005 Article Note: (footnote) The CREDO trial was sponsored by Bristol-Myers Squibb and Sanofi-Aventis. Dr. Steinhubl received research support from and served as a consultant for Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company, and served as a consultant for AstraZeneca and Accumetrics.